ArticleJournal of lipid research2009
The thyromimetic T-0681 protects from atherosclerosis.
Article in Journal of lipid research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 33 citations in OpenAlex.
- Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans.Journal of lipid research · 2014Trial
- Hepatic Energy Metabolism under the Local Control of the Thyroid Hormone System.International journal of molecular sciences · 2023Review
- Review
- Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges.Current atherosclerosis reports · 2016Review
- Article
- New avenues for regulation of lipid metabolism by thyroid hormones and analogs.Frontiers in physiology · 2014Review
- Nuclear receptors and their selective pharmacologic modulators.Pharmacological reviews · 2013Review
- Inhibition of hepatic scavenger receptor-class B type I by RNA interference decreases atherosclerosis in rabbits.Atherosclerosis · 2012Article
- Thyroid hormone enhances the ability of serum to accept cellular cholesterol via the ABCA1 transporter.Atherosclerosis · 2011Article
- The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice.PloS one · 2010Article
- The resurgence of thyromimetics as lipid-modifying agents.Current opinion in investigational drugs (London, England : 2000) · 2009Review
- Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs?Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 5 countries.
Funding
Abstract
This report describes studies in hyperlipidemic New Zealand White (NZW) rabbits investigating the impact of the liver-selective thyromimetic T-0681 on lipoprotein metabolism and the development of atherosclerosis. Prolonged treatment with T-0681 increased the hepatic expression of both LDL receptor and scavenger receptor class B, type I without affecting cholesteryl ester transfer protein activity. Upregulation of hepatic lipoprotein receptors was accompanied by a marked decrease of apolipoprotein B-containing lipoproteins, reflected by a 60% reduction of plasma cholesterol and a >70% reduction of plasma triglyceride levels. Most importantly, T-0681 reduced the development of atherosclerosis by 80% in NZW rabbits on high-cholesterol chow. Our data suggest that liver-selective thyromimetics, such as T-0681, may prove to be useful therapeutic agents against the development of atherosclerosis in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.